AIDS Treatment News - 1998

• AIDS Treatment News - 1998
• Issue #286
• 1998 Outlook: Treatment; Research; Access
• Efavirenz (Sustiva (tm) ) Expanded Access Now to 400 CD4
• San Francisco: Blood Needed for HIV Immunology Studies
• Treatment Conferences and Meetings, 1998


• Issue #287
• Marijuana, Inflammation, and CT-3 (DMH-11C): Cannabis Leads to New Class of Antiinflammatory Drugs
• Medical Marijuana: Federal, State Attacks Against California Cannabis Clubs
• Medical Marijuana: The Will Foster Case in Oklahoma
• Micronutrients and the HIV Patient, March 23-24 in Boston
• Scholarships Available for Geneva Conference: Application Deadline March 8
• More Attention to HIV Reporting As GMHC Changes Policy


• Issue #288
• Organ Transplants: Interview with Jeff Getty, on Ending the Exclusion of People with HIV
• HIV/AIDS in Prison Project Threatened: Interview with Judy Greenspan, Director
• 5th Retroviruses Conference in Chicago
• Adefovir Dipivoxil (PREVEON (tm) ): Expanded Access Restrictions Being Eased
• NTZ Submitted to FDA for Cryptosporidiosis


• Issue #289
• Clinical Implications of Virological "Failure": Interview with Steven Deeks, M.D., San Francisco General Hospital
• Retroviruses Conference Notes
• Retroviruses Conference: For More Information
• Opportunistic Infections: Major New Report


• Issue #290
• Drug Interactions: Resources for Patients and Professionals
• Medical Marijuana Update: New Threat to California Access; Activist Peron Qualifies for Governor's Race; New Scientist Ba
• Medical Advances with International Impact: Maternal Transmission; TB Prevention; Easier Sample Preparation Oral Contrace
• Oral Contraceptive / Nevirapine Interaction Trial, New York and San Francisco
• IL-2 Without Antiretroviral Therapy, Trial Near Washington D.C.
• FDA Publishes Conflict of Interest Rules for Clinical Trials


• Issue #291
• AIDS Treatment News Future Directions
• Fatigue and HIV: Interview with Lisa Capaldini, M.D.
• 1592 (Abacavir, or New Name Ziagen (tm)) More Widely Available March 23
• CD4 Increase Despite Protease Inhibitor "Failure" in Swiss Study
• March 25 Free Telephone Conference,
• Women's HIV Treatment Workshop, Oakland, California, March 28
• New FDA Commissioner Nomination Soon?


• Issue #292
• AIDS Survival: Major Improvement Documented
• Fatigue and HIV: Interview with Lisa Capaldini, M.D.Part II
• Nevirapine: One-Year Combination Results Published
• Notice on Efavirenz and Pregnancy
• AIDSWatch May 3-5 in Washington
• Medical Marijuana: Time to Contact Your U.S. Representative
• California AIDS Lobby Day, April 20 in Sacramento


• Issue #293
• T-20 and Trimeris
• Adefovir Dipivoxil (PREVEON) Improved Expanded-Access Program
• Adefovir Dipivoxil (PREVEON) New Results with Hepatitis B, HIV
• HIV/AIDS Nutrition Book for Clinicians
• Treatment Conference Call May 2
• Geneva Conference Communication Proposals for Minorities Due May 12
• New Priority Email Delivery from AIDS Treatment News


• Issue #294
• VIAGRA Warning re "Poppers" and Notice re Protease Inhibitors
• Preventing Mother-Infant Transmission Worldwide: What Is Needed? Interview with Joseph Saba, M.D.
• HIV Treatment Options
• Community Organizing by Email: Needle Exchange Mobilization Example
• 15th Annual Candlelight March, May 17
• San Francisco: Healing Alternatives Opens Castro Office


• Issue #295
• Hepatitis C : Important Treatment Advance: Interview with Douglas Dieterich, M.D.
• Hepatitis C and HIV: Ribavirin Plus Interferon Study Recruiting
• Metabolic Changes: Concerns About Heart, Circulatory Risks
• NTZ: Advisory Committee Votes Against Approval
• Update on AIDS Wasting and Lipodystrophy: One-Day Seminar in Geneva, June 28
• Geneva Conference: Call for Alternative and Traditional Healing Practices Material
• AIDS Vaccine: Major Report Available


• Issue #296
• New Guide to Living with HIV Infection
• Medical Marijuana: Largest Provider Closed, Some Alternatives Available
• Medical Marijuana Distribution Summit, Sacramento: Video Available
• Efavirenz (Sustiva(tm) ) and Saquinavir (Fortovase«) Combination: Pharmacologic Interaction
• If You Are Exposed to HIV: Guidelines Published for Postexposure Prevention
• Medical Marijuana Study in San Francisco: Pays $1000, 25 Days in Hospital
• Acetylcarnitine and Neuropathy: Call for Information
• Prison or Discharge Treatment Programs: Funding Available, Proposals Due June 29
• Correction: Hepatitis C Trial
• Email Experts; Librarians: AIDS Treatment News Seeks Expert Advice
• Prospective Case Series in Clinical Trial Design--Proposal, and NTZ Example


• Issue #297
• Agouron and Immune Response to Commercialize Remune (TM) Immune-Based Treatment
• 12th World AIDS Conference, Geneva, June 28 - July 3: How to Participate from Home
• Geneva Arrangements (If You Are Going)
• Metabolic Complications, Growth Hormone Treatment: New Studies Planned
• Ribavirin Approved for Hepatitis C Combination Treatment
• Pediatric HIV Treatment: Federal Guidelines Discussed July 22
• Congress: How You Can Help
• San Francisco: Six-Week Workshop on Returning to Work


• Issue #298
• HIV-Specific Immune Responses Restored by HIV Immunogen Plus Antiretroviral Suppression
• Successful Treatment of "Buffalo Hump" with Growth Hormone
• Geneva Conference Treatment Highlights
• AIDS Treatment News Internet Directory, http://www.aidsnews.org
• Women's Treatment Information and Advocacy: Position at Project Inform
• San Francisco, Oakland: Treatment Access and Information Workshop, July 24, July 31, or August 14
• Correction: Last Issue Date
• Scientific American July Special Report on AIDS


• Issue #299
• Efavirenz (Sustiva (tm)) May Equal or Exceed Protease Inhibitor in Initial Antiretroviral Combination
• Viral Resistance Overview
• Fusion inhibitors, T-20; Chemokine Variants; Tat and Interferon Antibodies: Gallo Describes Three New Treatment Approache
• Geneva Conference: Finding Information on the Web and Elsewhere
• AIDS Diarrhea: Phase III Trial Recruiting in Over 30 U.S. Sites
• San Francisco: Geneva Conference Review, July 22


• Issue #300
• T-20: New Trial Enrolling, 9 U.S. Cities
• Ritonavir Capsule Manufacturing Problems Will Require Switch to Liquid Formulation
• New Vaccine+HAART Treatment Trial Enrolling at NIH
• Geneva Medical Report Now on Web
• Viral Load: Roche Applies for Marketing Approval for Ultrasensitive Test
• IHV 1998 Annual Meeting (Gallo Lab Meeting) August 23-29 in Baltimore
• Geneva Update Town Hall Meeting, August 17, Redwood City, California
• San Francisco: Employment-Issues Training for Service Providers, August 19
• AIDS Meals and Nutrition Conference, Sept. 10-13, San Francisco
• Rural AIDS Conference, September 10-12, Albuquerque
• Hepatitis C Conference, August 23-25 in Oakland
• Medical Marijuana: Healing Alternatives Begins Distribution
• Nutritional Supplements: Call for Information


• Issue #301
• The CHORUS Database on Patient Clinical Care--and Interview with Stephen Becker, M.D.
• Retroviruses Conference, Jan. 31 - Feb. 4, 1999, Chicago: Abstract Deadline October 1
• International Healthcare Resource Allocation Conference, November 15-18, Canc·n, Mexico
• Herbal Medicine Safety Workshop, National Institutes of Health, Research Triangle Park, September 23 and 24
• Medical Marijuana: Strong Support in Oakland
• San Francisco: Forum on Body Composition Changes, September 1
• San Francisco: Intensive Seminar on Benefits, September 10-11
• Help Wanted: Assistant Director, Forum for Collaborative HIV Research
• Major Email Security Flaws Discovered: How to Protect Your Data


• Issue #302
• Post-Exposure Prevention (PEP); What to Do If the Condom Breaks?
• New Drug Pricing Consensus Letter, Sign-Ons Requested
• Hepatitis C: New Treatment Overview
• HIV and Hepatitis Physician Education, San Francisco Sept. 12
• IHV 1998 Annual Meeting (
• Fomivirsen Approved for CMV Retinitis: First Antisense Drug
• Prison Issues: National Conference, Web Sites
• Help Wanted: Executive Director, Project Inform


• Issue #303
• Lipodystrophy Research Coordination Needed
• ICAAC Report, September 27, by Telephone Conference
• PMPA Trials Recruiting: Atlanta, (Baltimore), Berkeley, Birmingham, Brookline, Chicago, Cleveland, Dallas, Denver, Hershe
• Improved Viral Load Test: Open Letter on FDA Approval
• Acupuncture Research Symposium, Sept. 26-27 at Stanford University
• Indigenous Nations AIDS Conference, Prior Lake, Minnesota, September 27-30
• Titillationism--Or, Register Now to Vote!


• Issue #304
• Efavirenz (SUSTIVA (tm)) Approved
• Crixivan« (Indinavir): Three Doses Daily, Not Two, in Most Regimens
• Amprenavir (Agenerase (tm)) Now Available in Expanded Access
• Successful Standard Treatment for Lipid Abnormalities: Experience with 44 Patients
• ICAAC Conference: Daily Summaries Available
• Abacavir (Ziagen (tm)) Advisory Committee Meeting, November 2
• Prison Treatment Programs: Glaxo-Wellcome Awards 19 Grants
• Iscador Update: Interview with Robert Gorter, M.D.
• United States Conference on AIDS, Dallas, Oct. 29 - Nov. 1
• San Francisco: POZ Life Expo, October 16-17


• Issue #305
• California ADAP Alert
• Retroviruses Conference Scholarship Deadline Nov. 3
• San Francisco: Body Shape Changes, Lipodystrophy Community Forum Oct. 19
• AmFAR RFPs: Immune Reconstitution, HIV Vaccines; Grants $75,000 to $150,000, Letter Due November 4
• Oakland, California: Oct. 22 Panel on Alternative Treatments
• Nelfinavir (Viracept«) Price Increase 4.6%
• 11th National HIV/AIDS Update Conference; Abstract Submission Deadline November 1
• Association of Nurses in AIDS Care, November 15-18, San Antonio
• San Francisco: Hepatitis C Community Forum, Oct. 20
• Cannabis and Cannabidiol: Interview with Robert Gorter, M.D.


• Issue #306
• T-20 Results Published
• U.S. Testosterone Shortage: Call for Information
• Abacavir (Ziagen (tm)) Approval Recommended
• Induction/Maintenance Strategy Failed in U.S., French Trials
• Efavirenz (Sustiva (tm)) Available through Patient Assistance Program
• Amprenavir (Agenerase (tm)) Submitted for Approval
• National AIDS Treatment Advocates Forum, December 5-8, Philadelphia
• Glasgow Conference Reports on Web
• Lipodystrophy, Anemia, Resistance, Other Articles ...
• New TB Guidelines for Persons with HIV
• Alitretinoin Gel (Panretin«) FDA Hearing November 16
• Record AIDS Funding from Outgoing Congress
• Help Wanted, AIDS Treatment Writer, New York
• California: Medicaid Expansion Needs Quick Attention after the Election
• Youth Consent, Confidentiality for Counselors, San Francisco December 1
• California ADAP Update


• Issue #307
• GATT and the Gap: How to Save Lives
• Testosterone Cream and Gel Available; Prices Vary Greatly
• Urgent: Medicaid Rule Changes, Comments Due November 30
• Health Insurance: New NAPWA Guide
• Flu Season Protection: Information on Web
• Retroviruses Conference: Press Must Register by December 31 or Earlier
• Medical Marijuana Wins 7 of 7 U.S. Elections
• Northern California: HIV Advocacy Conference, December 12-13
• Free Newsletter Subscriptions Through Medical Practices, Clinics


• Issue #308
• Major Vaccine Project: Largest AIDS Research Grants Ever to Two "Most Promising" Approaches
• Disability and Returning to Work: Proposed Change to Let Disabled Keep Benefits
• Low-Dose Cyclosporin: Government Trial Recruiting, CD4 Count Over 500 ( Baltimore, Cambridge, Chapel Hill, Chicago, Cleve
• IDSA Conference: Abstracts on the Web
• 4th International Congress on Drug Therapy in HIV Infection: Summaries on Web
• New Drug Pricing: Progress on World AIDS Day?


• Issue #309
• Complementary Treatments: Dr. Kaiser's New Book
• AIDS Treatment News January Publication Schedule
• Buyers' Club List, December 1998
• AIDS Treatment News Index, 1998

All information on AIDS.ORG is designed to support, but not replace your relationship with your doctor, and is intended soley for educational or research purposes. Any and all personal information you may provide us with is never released to anyone at any time. Your privacy and trust is extremely important to us.

• News
• Topics
• Experience
• Donate
• About Us

• Headlines
• AIDS Treatment News